Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2016 · 10-Q
Revenue$2.48M$2.48M−22.8% vs Q3 2015 Net Income-$3.15M-$3.15MN/M vs Q3 2015 EPS Diluted-$0.96-$0.96N/M vs Q3 2015 Gross Profit$455,000−72.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,691,000N/M Free Cash Flowderived-$2,815,000N/M Margins · derivedGross margin18.3%−33.1 pt vs Q3 2015
Operating margin-168.7%−108.1 pt vs Q3 2015
Net margin-126.8%+57.0 pt vs Q3 2015
ended Dec 31, 2015 · filed Feb 16, 2016 · 47 d after period end